Treatment of ovarian hyperstimulation syndrome using gonadotropin releasing hormone antagonist: a pilot study.
OBJECTIVE
This novel study describes an effective outpatient treatment for ovarian hyperstimulation syndrome (OHSS) that results in rapid normalization of symptoms.


METHODS
A total of twenty-seven infertile women undergoing assisted reproductive technique with early-onset OHSS were enrolled in this non-randomized clinical trial in an academic infertility center. In all patients, after complete desensitization with long-term protocol ovarian stimulation with gonadotropins was commenced. Final oocyte maturation was triggered with human chorionic gonadotrophin. Oocytes were collected 36-38 h later using transvaginal-guided follicle aspiration under general anaesthesia. All embryos were frozen and study group patients received two consecutive doses of GnRH antagonist (Cetrotide) and the control group received daily dose of cabergoline for a week.


RESULTS
The research revealed that moderate and severe OHSS, hospitalization or acute care for OHSS and ascites tap were significantly lower in the antagonist (Cetrotide) group. The Patients' satisfaction with Cetrotide was noticeable. No side effect was reported in either group.


CONCLUSIONS
GnRH antagonists seem to be an effective outpatient treatment with rapid onset activity and minimal side effects for the management of early OHSS.
Department of Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Marzieh Agha
MA
Hosseini
Atossa
A
Mahdavi
Ashraf
A
Aleyasin
Leili
L
Safdarian
Fatemeh
F
Bahmaee
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077465:Cabergoline; D004873:Ergolines / Q000627:therapeutic use; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D006727:Hormone Antagonists / Q000627:therapeutic use*; D006801:Humans; D016471:Ovarian Hyperstimulation Syndrome / Q000188:drug therapy*; D010865:Pilot Projects; D055815:Young Adult
D000970:Antineoplastic Agents; D004873:Ergolines; D006727:Hormone Antagonists; D007987:Gonadotropin-Releasing Hormone; D000077465:Cabergoline; C062876:cetrorelix